Flow cytometry and clonality evaluation are effective for characterizing feline lymphoma

August 12, 2024

A new study showed that this cell-sizing method is useful for characterizing feline lymphoma and predicting patient survival time

--

This article is written by Abi Bautista-Alejandre and published in DVM360.

--

Recent research has determined flow cytometry and clonality evaluation as a reliable method for characterizing feline lymphomas. Lymphoma is one of the most prevalent cancers in cats, with almost 30% of all feline cancers being lymphoma cases.1 Moreover, the size of neoplastic cells is a key factor in determining prognosis, with survival time being dependent on cell size, the study found.2 This new cell-sizing method will help provide prognostic insights and affect treatment decisions, according to a news release.1

Flow cytometry is a technique used for rapidly analyzing multiple parameters of single cells suspended in a solution. It uses lasers to generate scattered and fluorescent light signals, which are read by detectors such as photodiodes or photomultiplier tubes. These light signals are then converted into electronic signals, analyzed by a computer, and written to a standardized data file format (.fcs). Cell populations can be analyzed and/or purified based on their light scattering and fluorescent properties, according to literature on flow cytometry.3 Flow cytometry is commonly used to identify and characterize lymphomas in dogs and humans. Yet, its use in cats has scarcely been explored.1

For the study, researchers explored the usefulness of flow cytometry and clonality analysis via polymerase chain reaction (PCR) for antigen receptor rearrangement (PARR) for characterizing feline lymphoma and predicting prognosis. They analyzed fine needle aspirates and/or blood samples from 438 feline patients using flow cytometry and PARR, and compared a subset of results from patients with confirmed B- or T-cell lymphomas to cytological or histological evaluations. The most optimal set of flow cytometry parameters, principally forward scatter thresholds, were identified to improve cell size categorization.1,2

The flow cytometry and clonality evaluation method proved to be 82% concordant with the gold standard of cytology. Specifically, this method exhibited 82% concordance with cytological measurements in a training set and 90% concordance in an independent test set.1,2

Further research involving more patients revealed notable differences in survival rates. Cats with small-cell lymphomas had the longest survival, with a median of 312 days. Meanwhile, those with medium-cell lymphomas had a median survival time of 189 days. Cats with large-cell lymphomas had the shortest survival of a median of 81 days. The lymphoma subtypes identified through flow cytometry and PARR showed significant variations in survival, highlighting the method’s potential for prognostic assessment.1,2

“The proposed methodology achieves high concordance with cytological evaluations and provides an additional tool for the characterization and management of feline lymphoproliferative diseases,” the authors wrote.2

The study was conducted by ImpriMed, a precision medicine startup that uses artificial intelligence (AI) in cancer treatments. The company announced an upcoming study on AI-powered prognostication for feline lymphoma that seeks to advance predictive analytics for individualized treatment plans for patients. This recent study establishes a foundation for the forthcoming study, according to a news release.

"We are thrilled to share our breakthrough findings with the veterinary community," Sungwon Lim, ImpriMed’s CEO and co-founder, said in the release.1 "Our innovative cell-sizing method is a significant advancement in the fight against feline lymphomas, equipping veterinarians nationwide with enhanced tools for accurate diagnosis and effective treatment of this challenging disease.”

References

  1. ImpriMed unveils groundbreaking cell-sizing method for high-accuracy feline lymphoma characterization in Veterinary Sciences. News release. ImpriMed. August 12, 2024. Accessed August 12, 2024. [email]
  2. Kapoor S, Sen S, Tsang J, et al. Prognostic utility of the flow cytometry and clonality analysis results for feline lymphomas. Veterinary Sciences. 2024;11(8):331. https://doi.org/10.3390/vetsci11080331
  3. McKinnon KM. Flow cytometry: An overview. Current Protocols in Immunology. 2018;120(1). 10.1002/cpim.40

In the News

How Artificial Intelligence Is Revolutionising Cancer Care for Pets

Pets Magazine
Learn More →

Artificial Intelligence Takes on Cancer: The Only AI Dr. Karyn Doesn’t Hate

Dogster
Learn More →

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Pharmacy Times
Learn More →

Cancer Treatment Gets Personal: How Artificial Intelligence Is Taking the Guesswork Out of Common Canine Cancers

Dogster
Learn More →

Ilona Holcomb on How ImpriMed’s AI is Transforming Cancer Treatment for Pets and Humans

Biopharma Boardroom
Learn More →

From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology

Pharmacy Times
Learn More →

ImpriMed unveils cancer treatment forecast technology

MobiHealthNews
Learn More →

New research evaluates flow cytometry and PARR as diagnostic support for feline lymphoma

American Animal Hospital Association NEWStat®
Learn More →

Cell-sizing method for high-accuracy feline lymphoma characterisation in veterinary sciences

Veterinary Practice
Learn More →

ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market

Pulse 2.0
Learn More →

New AI Tool Guides Canine Cancer Treatment

Today's Veterinary Business
Learn More →

Artificial intelligence poised to transform veterinary care

AVMA News
Learn More →

New AI service offers personalized drug response predictions for canine patients with cancer

DVM360
Learn More →

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

TechCrunch
Learn More →

ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment

USA Today
Learn More →

Data Science Can Markedly Improve Cancer Treatment Outcomes — ImpriMed Shows You How

Innovative Veterinary Care Journal
Learn More →

How ImpriMed Can Help Increase Cancer Remissions, Grow Your Reputation and Level Up Your Revenue

Innovative Veterinary Care Journal
Learn More →

ImpriMed: A Breath of Fresh Air for Traditionally Onerous Cancer Treatment Journeys

Innovative Veterinary Care Journal
Learn More →

ImpriMed: Revolutionizing Canine Cancer Treatment with Precision and Personalization

International Business Times
Learn More →

New AI Technology From ImpriMed Helps Improve Cancer Treatment Success Rates in Your Practice…and Fosters Better Relationships

Innovative Veterinary Care Journal
Learn More →

The latest and greatest in canine oncology treatment

DVM360
Learn More →

Get Rid of Your Cancer Treatment Frustrations

Innovative Veterinary Care Journal
Learn More →

Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator

MedCity News
Learn More →

Be sure to improve your cancer treatment outcomes

Innovative Veterinary Care Journal
Learn More →

Early leukemia and lymphoma remissions in cats and dogs

Innovative Veterinary Care Journal
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)

One Million by One Million
Learn More →

Technological advancement makes cancer treatment easier

Innovative Veterinary Care Journal
Learn More →

Novel veterinary oncologic treatments and diagnostics

dvm360
Learn More →

AI’s Computing Power Could Make Fusion Energy Practical

Lifewire
Learn More →

Don't Guess Your Pet's Condition, Treat It with ImpriMed

Startup to Follow
Learn More →

Interview with ImpriMed CEO & Co-Founder Sungwon Lim

IdeaMensch
Learn More →

This Test Might Make All The Difference When Fighting Lymphoma

Canine Cancer Alliance
Learn More →

ImpriMed: Fighting Cancer — From Dogs To Humans

Startup Thread
Learn More →

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

TechCrunch
Learn More →